Berge M, Koppelman GH, Postma DS. PTTG1IP and MAML3, novel genomewide association study genes for severity of hyperresponsiveness in adult asthma. 
Bronchial hyperresponsiveness (BHR) is a hallmark of asthma (1) . The severity of BHR varies between asthmatics and is associated with the degree of underlying airway wall inflammation and structural changes, for example smooth muscle mass, fibrosis and remodelling (2) . More severe BHR associates with lack of asthma control (3) . The use of inhaled corticosteroids (ICS) does improve but generally not normalize BHR (4, 5) , while smoking worsens BHR (6) . The severity of BHR can be measured with a PC 20 or with a slope of the dose-response curve after inhalation of increasing doses of, for example methacholine. The advantage of a slope over a PC 20 is that the full spectrum of FEV 1 response can be evaluated. Thus, patients using steroids, and as a consequence not reaching a 20% drop in FEV 1 , can still be included in a study on the severity of BHR (7) .
Genetic studies can be used to obtain better insights in the mechanisms underlying a trait. A few genetic studies have been performed on the severity of BHR in asthmatics of Caucasian descent. In childhood, one genomewide association study (GWAS) (8) and several candidate gene studies (9) (10) (11) (12) (13) (14) (15) have shown associations of AGFG1, ADRB2, GPR154, TBX21, VEGF and FCERIB with the severity of BHR. In adulthood, there is no GWAS study available in the literature, yet three candidate gene studies (16) (17) (18) have provided suggestive evidence of an association between ADRB2 and the severity of BHR.
Our aim was to identify genes associated with the severity of BHR by performing a GWAS on the slope of BHR in adult asthmatics and to attempt replication in other cohorts. Additionally, eQTL analyses and co-expression analyses in lung tissue were performed together with gene set enrichment analysis of all GWAS data on severity of BHR.
Methods

Study populations and phenotype definition
Patients with asthma were recruited from the Dutch Asthma GWAS (DAG) cohort. All cases were of Caucasian descent and had a doctor diagnosis of asthma combined with BHR. All participants had data available on smoking and ICS use at the time of testing.
All subjects performed a challenge test using either histamine or methacholine according to standardized protocols (19) . The BHR slope was calculated by dividing the difference between FEV 1 at baseline and at the dose step at which a ≥20% fall in FEV 1 was reached or the highest dose inhaled, by the dose that was taken at this last step. We divided the BHR slopes of the 30-s tidal breathing method by 4 to compare the slope of the 30-s and the 2-min tidal breathing methods (20) . Values were log-transformed (Ln) to reach normal distribution. The formula of the calculation of the slope is shown in the Supporting information.
Genotyping and GWAS
DNA of subjects was genotyped with the Illumina 317k Chip or with the Illumina 370k Duo Chip (Illumina Inc, San Diego, CA, USA), for further details see Supporting information. Quality control was applied; subjects were removed from analysis if they were not of Caucasian descent based on principal component analysis (Fig. S1 ), had a low genotyping call rate (<95%) or were discrepant or ambiguous for genetic sex. SNPs were deleted if the call rates were low (<95%), not in Hardy-Weinberg equilibrium (P < 1*10
À4
), or if the minor allele frequency was <0.05. After quality control, 294 932 SNPs were selected for analysis.
All statistical analyses were performed using PLINK v1.07 (http://pngu.mgh.harvard.edu/ $ purcell/plink/). Linear regression analyses were performed using an additive genetic model to analyse the effect of SNPs on BHR slope with adjustments for smoking and inhaled and/or oral corticosteroid use. Smoking was labelled as never (reference), current or ex-smokers, and ICS use, according to time stopped before the challenge test: (i) never used steroids or stopped >4 weeks (reference), (ii) stopped between 2 and 4 weeks or (iii) stopped between 0 and 2 weeks before the challenge test.
P-values < 1.70*10 À7 were considered genomewide significant, based on the Bonferroni corrected P-value of <0.05. SNPs with P-values < 1*10 À5 were selected for replication.
SNPs with a P-value < 0.05 in one of the replication cohorts with the same direction of effect in all cohorts were considered nominally replicated. In addition, we performed a metaanalysis on the replication cohorts.
Replication populations
Replication analysis on the severity of BHR in asthma was performed in the CAMP (8), EGEA (21) and ECRHS (22) studies. An overview of the inclusion characteristics, ethnicity and (short) study methods of the replication cohorts is presented in Table 1 .
Gene expression
Cis-eQTL analyses were performed on the replicated SNPs using linear regression models in a lung tissue database of three centres as previously published (23) . Adjustments were made for principal components, age, gender, smoking and all other lung diseases like cystic fibrosis, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Data of the three centres, that is University of British Columbia (UBC), Laval and Groningen, were analysed separately and subsequently meta-analysed.
Literature search on genes of interest
A literature search on the eQTL genes that we found in our main analyses was performed to find new genes either functionally or by expression related to the former eQTL genes. In our lung tissue database, we correlated the observed gene transcripts regulated by eQTLs from our main analyses with the gene transcripts of genes found in the literature using a Pearson correlation with Bonferroni correction.
Database analysis
A pathway analysis was performed by loading results of the GWAS on severity of BHR onto the i-GSEA4GWAS server (gsea4gwas.psych.ac.cn) (24) . All pathways with an FDR P < 0.05 are presented. Functional annotation of the replicated SNPs and their proxy SNPs (r 2 > 0.8) were evaluated using RegulomeDB (25) . SNPs with data on gene expression (eQTL), motifs and protein binding were presented. Furthermore, Haploreg (26) was used to evaluate SNPs with data on histone marker, DNase, protein binding, motifs and eQTLs. Finally, replicated SNPs were tested for eQTLs in lung tissue using GTEx (27) .
Results
Patient characteristics
The mean age in the DAG Cohort was 36 years; 45% of the asthmatics were male ( Table 2 ). The CAMP study only included asthmatic children whose PC 20 was measured at a 20 methacholine was available in ECRHS, but 58% of asthmatics had a 20% fall in FEV 1 by the time they had reached inhalation of 1 mg methacholine, whereas this was the case in 32% of the asthmatics in the DAG cohort.
GWAS results
The Manhattan plot of the GWAS on the severity of BHR in the DAG cohort is shown in Fig. 1 . There was no evidence of population stratification as can be seen in the Q-Q plot (Fig. S2 ). One SNP in PDE4D (rs4700365) reached genomewide significance with a P-value of 1.4*10
À7
, and 26 SNPs showed suggestive evidence with P-values < 1*10
À5
. Twenty-five SNPs were further assessed for replication, two being excluded due to high linkage disequilibrium (LD) (i.e. r 2 ≥ 0.8) between the SNPs (rs4700365 and rs983280 both located in PDE4D).
Replication results
The severity of BHR can differ between children and adults (28, 29) . The CAMP study included children only. To assess whether we could replicate our findings in adults specifically, we analysed our data without the CAMP study. Two SNPs replicated nominally in the ECRHS and had the same direction of effect in EGEA. The first SNP (rs1344110) was located in the gene pituitary tumour-transforming 1 interacting protein (PTTG1IP) and was associated with less severe BHR (P-value meta-analysis of identification and replication cohorts 7.22 9 10
À5
). The second SNP (rs345983) was located in the intronic region of the gene Mastermind-like 3 (MAML3) and was also associated with less severe BHR (Pvalue meta-analysis of identification and replication cohorts 4.49 9 10
À4
; Fig. 2 ). In addition, none of our discovery findings had a P-value < 0.05 in a joint meta-analysis of the two adult cohorts and in a joint meta-analysis of the two adult cohorts and childhood cohort (Table S1 ). Our genomewide significant hit in PDE4D did not replicate in the any of the cohorts.
Gene expression
Both nominally replicated SNPs were selected for eQTL analyses in lung tissue. Two probes in PTTG1IP and six probes in MAML3 were present in the lung tissue database. Based on Bonferroni correction, a P-value of 0.05/8 = 0.006 was considered significant. Both probes in PTTG1IP showed a significantly higher gene expression with every added minor allele of rs1344110 (probe 1: b = 0.06, P = 9.92*10
À21
; probe 2: b = 0.06, P = 5.10*10
À27
). The minor allele of the SNP in MAML3 (rs345983) was associated with a significantly higher expression in one of the MAML3 probes (b = 0.17, P = 1.35*10
À11
; Table 3 ).
Literature search on genes of interest
The protein PTTG1IP is known to bind PTTG1 in the cytosol and aids the transport of PTTG1 into the nucleus (30, 31) . PTTG1 has been associated with two genes of interest for BHR: VIM (vimentin) and CDH1 (E-cadherin1). Both genes, VIM and CDH1, are linked to epithelial-mesenchymal transition (31) . Epithelial-mesenchymal transition is important in asthma, as both smooth muscle hypertrophy and hypercontractility and airway wall changes can contribute to the severity of BHR.
Proteins of MAML3 and MAML1 form a complex with MAML2, thereby influencing Notch signalling (32) . Notch Figure 1 Manhattan plot of the genomewide association study (GWAS) on the severity of bronchial hyperresponsiveness in Dutch Asthma GWAS cohort. Red line shows genomewide significant P-value.
signalling itself has been involved in increased airway inflammation and fibrosis in mouse models of asthma (33) .
We assessed the correlation of PTTG1IP expression with the expression of PTTG1, VIM and CDH1 and the correlation of MAML3 expression with the expression of MAML1, MAML2, NOTCH1, NOTCH2, NOTCH3 and NOTCH4.
PTTG1IP had a significant, negative correlation with PTTG1 (r = À0.14; À0.25) and positive correlation with VIM (r = 0.20; 0.38) and CDH1 (r = 0.12; 0.54). MAML3 had a significant positive correlation with MAML2, but did not show a significant correlation with any of the NOTCH transcripts (Table S2a,b).
Database analysis
All GWAS results were loaded onto the website of i-GSEA4GWAS and analysed. We found several significant pathways (Table S3) , of which the smooth muscle contraction pathway (FDR = 0.04) is of specific interest for the severity of BHR.
Functional annotation with RegulomeDB, Haploreg and GTEx was performed on the replicated SNPs rs1344110 and rs345983. Rs1344110 was in LD with 13 other SNPs located in the intronic region of PTTG1IP (10 SNPs) and in the 5 0 region of SUMO3 (three SNPs). In total, 14 SNPs (the replicated SNP and 13 SNPs in LD) were studied. Results of all 14 SNPs are shown in Table S4 . Rs1344110 is situated in a histone enhancer region in six different tissues and constitutes an eQTL in PTTG1IP, SUMO3, UBE2G2, LINC01547 and FAM207A. In total, the 14 SNPs were associated with changes in 50 motifs and 93 protein bindings. After uploading rs1344110 for lung eQTLs in GTEx, one lung eQTL was found with an effect size of 0.41 and P-value of 1.08*10
À13
. The SNP located in MAML3 (rs345983) was in LD with one other MAML3 SNP rs1039948 (r 2 = 0.92). Both SNPs changed one motif; rs345983 IRF4 and rs1039948 E47.
Rs345983 showed protein binding with one protein (POLR2A) ( Table S4 ). Rs1039948 showed protein binding with four other proteins: E2A, LMO2, TAL-1 and ZEB1. No significant lung eQTLs were found in GTEx.
Discussion
To our knowledge, this is the first time that the underlying genetic regulation of BHR severity in adult asthma has been studied by GWAS. Bronchial hyperresponsiveness is a core feature of asthma, and its severity is associated with instability of asthma (3). Our main finding is the identification of PTTG1IP and MAML3 as novel genes associated with the severity of BHR. The minor allele of rs1344110, located in the intronic region of PTTG1IP, was associated with less severe BHR in asthma and a higher gene expression of PTTG1IP in lung tissue. Furthermore, higher PTTG1IP expression was associated with lower PTTG1 expression and higher VIM and CDH1 expression in lung tissue, all compatible with less severe BHR in asthma. The minor allele of rs345983, located in the intronic region of MAML3, associated with less severe BHR and showed suggestive evidence of a higher expression of the gene MAML3 in lung tissue as observed in one of the six probe sets. A higher expression of MAML3 was associated with a higher expression of MAML2, which theoretically can lead to less Notch signalling resulting in less inflammation, compatible with less severe BHR. PTTG1IP is highly conserved across a diversity of animal species; therefore, it is an evolutionary important gene. PTTG1IP has been associated with several forms of cancer, but has not been studied so far in relation to BHR, asthma or expression in lung tissue. The question rises why PTTG1IP might contribute to the severity of BHR in asthma. Bronchial hyperresponsiveness severity is determined by multiple intrinsic and extrinsic factors. Examples of intrinsic factors that contribute to airway narrowing and thereby BHR severity are among others loss of epithelial barrier function, increased airway smooth muscle mass and shortening, airway wall remodelling and airway wall thickening by inflammation and oedema (34, 35). The protein PTTG1IP is known to bind PTTG1 via its nuclear localization signal thereby aiding the transport of PTTG1 from the cytosol into the nucleus, leading to transcription of many proteins (30, 36) . PTTG1 has been associated with an increase of vimentin and a decrease of E-cadherin1 in A549 as well as H1299 cell lines (31) . Our study in lung tissue, in contrast, shows that higher PTTG1IP expression correlates with higher vimentin expression, which may be due to different cell types and tissues studied. vimentin is associated with the differentiation of fibroblasts to myofibroblasts, which may contribute to hyperplasia of the basal membrane and, in association with airway remodelling, can lead to thickening of the airway wall (37) . Thickening of the airway wall in turn may lead to increased stiffness of the airways (35, 38) . Thus, airways better resist dynamic compression by smooth muscle contraction, resulting in less severe BHR.
We also show a positive correlation between expression of PTTG1IP and CDH1 in lung tissue. A higher CDH1 expression reflects more E-cadherin1 in the epithelium, which has been shown to contribute to better epithelial barrier function and epithelial integrity (38) (39) (40) . Induction of E-cadherin1 also associates with inhibition of NF-jB signalling, which could lead to a tolerogenic phenotype of the airway epithelium. Of interest, one of the SNPs (rs2277810) in LD with our SNP (rs1344110) in PTTG1IP leads to a motif change in NF-jB. Furthermore, E-cadherin1 is associated with tolerance induction of CD103 + immune cells. CD103 is expressed on Tregs cells that are capable of suppressing Th2-driven asthma manifestations (39, 40) . All these mechanisms related to E- cadherin1 can contribute to less severe BHR (see Fig. 3 for an overview of the suggested pathways). MAML3 has been associated with chronic mucus hypersecretion in COPD (41), without any report in asthma on a genetic level. Deletion of MAML3 has been associated with loss of Notch signalling in mice (32) . Less Notch signalling in turn has recently been associated with less Th2 differentiation and therefore less inflammation in mice (33) . If this is also the case in human asthma, this would be compatible with less severe BHR, and thus with the negative association of rs345983 in MAML3 and severity of BHR in asthma as shown in our data ( Table S2b) . As the expression of MAML3 did not correlate with NOTCH1-4 expression, it is not clear whether the proposed mechanism is active in the human lung; this clearly needs further study.
We performed a study on the severity of BHR and found some genetically driven pathways related to this asthma trait. The question remains whether these genes are also associated with different asthma traits, like bronchodilator reversibility of severity of lung function. This clearly requires larger cohorts in future GWAS studies.
Severity of BHR is also dependent on other factors such as gender, age, smoking and ICS use. When comparing the replication cohorts and the DAG cohort, we find some differences that may explain the low replication success of our SNPs (Table 2) . Age is comparable between the ECRHS, EGEA and DAG cohort, although the DAG cohort included a small proportion of children (<7%), whereas the CAMP study only included children. Genetic analyses on asthma have shown differences in adults and children; for example, ORMDL3 is specifically associated with childhood asthma (42) . We here show that the genetic underlying mechanisms of the severity of BHR can be different between children and adults as well. This can among others be due to effects of smoking exposure and ICS use on the severity of hyperresponsiveness. Therefore, we also studied results in adults separately. This improved the results but not to a genomewide significant level. Furthermore, the DAG cohort has relatively more severe asthmatics as suggested by lower lung function and higher ICS use when compared to the ECRHS and the EGEA cohorts. ECRHS had the most severe BHR and EGEA the least severe BHR, and this could be a reason why our finding best replicates in the ECRHS cohort, that is a greater risk estimate in more severe asthma.
Asthmatics in the DAG cohort either were challenged with methacholine or histamine, while the EGEA, ECRHS and CAMP study all used methacholine. However, when we stratified our analysis in the DAG cohort for methacholine and histamine, the effect sizes and directions of effect were comparable, hence not explaining differences between cohorts (Table S5a) , although we did observe somewhat lower lung function and higher ICS use in those tested with histamine (Table S5b) . PC 20 and slope are often used to study the severity of BHR. In this study, the slope is used to measure the severity of BHR to include as many individuals as possible in our analysis. A sensitivity analysis was performed on our top results to check whether the use of the PC 20 would lead to different results, which was not the case (Supporting information). Furthermore, an analysis with PC 20 corrected for FEV 1 was performed, to adjust for baseline FEV 1 as this may affect the PC 20 value. As can be seen in Table S6 , comparable results were found when using a PC 20 , PC 20 corrected for FEV 1 and slope.
The eQTL in MAML3 was only significant in one of the six probe sets of MAML3 in the lung tissue database. After performing a qPCR analysis on a small subset of 54 patients of the lung tissue database from whom we still had lung tissue available, we could not confirm this eQTL. We did, however, see the same direction of effect (b = 0.33, P = 0.16). This lack of replication could be due to the different samples of lung tissue and location in the lung, the difference in genetic location of the probe set used for qPCR analysis and eQTL analysis or because of the low number of subjects used in this analysis.
Although our cohort contains a reasonable number of participants with measurements of BHR, smoking and steroid use, the power of finding a genomewide significant hit is still low (power = 0.11). Due to only nominal replication, genes found in the analyses, even when plausible, should be seen as suggestive genes and further genes could be found in a more powerful study.
Our study design was based on identification of significant SNPs in the largest cohort and replication of the identified SNPs in several smaller cohorts. It is important to note that another approach, for example a meta-analysis of GWAS results of all cohorts, may have led to different results.
Notwithstanding the differences between the cohorts studied, we found replication of SNP rs1344110 in PTTG1IP. This SNP and the LD SNPs had several regulatory functions, like eQTL, motifs and protein binding. When studying the motifs, rs17219671 was associated with a motif change in oestrogen-related receptor alpha (ESRRA), beta (ESRRB) and gamma (ESRRG). A previous study found an interaction between a tandem repeat in PTTG1IP (not available in our dataset) and ESRRA in relation to the risk of breast cancer (43) . Although this interaction has never been studied with respect to the severity of BHR, it could be of interest since a previous publication from our group showed that oestrogen receptor1 (ESR1) associated with the presence of BHR (29), and in the current study, we found an association between the severity of BHR and ESR1 in our discovery cohort (Table S1 ). Interestingly, the minor alleles of PTTG1IP and ESR1 show a trend for interaction with respect to the severity of BHR and are co-expressed in our lung tissue database (Table S7a,b) . Further studies are needed to support this observation.
Several candidate gene studies have associated ADRB2 to the severity of BHR in asthmatic adults (16) (17) (18) . We could, however, not confirm these observations (data not shown). PDE4D, the gene that was genomewide significantly associated with BHR severity in the discovery analysis but not replicated, has been associated with asthma in a previous study (42) . The SNPs found in the latter study are the same or in high LD with one of the top results found in our study (rs983280) (44) . Another study investigated the relation to airway smooth muscle relaxation and contractility. This study investigated isolated Pde4dÀ/À tracheas of mice and found a fivefold decrease in sensitivity to muscarinic cholinergic agonists, like methacholine, as compared to Pde4d+/+ (45). This decrease in sensitivity might be related to less severe BHR in patients with asthma who had the PDE4D minor allele in our discovery cohort. However, future studies in asthmatics with more severe BHR are needed to confirm this.
In conclusion, we found two novel genes, PTTG1IP and MAML3, to be significantly associated with the severity of BHR in a meta-analysis of three adult cohorts and with the same direction of effect in a fourth cohort with childhood asthma. The relevance of PTTG1IP was supported by the fact that the gene drives gene expression in lung tissue and that it is coregulated with E-cadherin1 and vimentin, proteins that plausibly contribute to the severity of BHR. The relevance of MAML3 can be found in the Notch signalling pathway, which could lead to less inflammation in the airways. Future functional studies should investigate the role of PTTG1IP in the severity of BHR in more detail.
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